CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,225 enrolled
Drug / intervention
solifenacin succinatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00463541
NCT00463541Phase 3Completed
CompareCT.gov

An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial

Astellas Pharma Inc·interventional·Posted Apr 20, 2007·Updated Sep 18, 2014

In Brief

A Phase 3 clinical trial evaluating solifenacin succinate for Urinary Bladder, Overactive. Completed, enrolled 2,225 participants across 198 sites.

Detailed Summary

To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 20, 2007
Enrollment StartJun 1, 2004
Primary CompletionApr 1, 2005
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.2 years ago

Interventions

solifenacin succinatedrug

oral